Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-infected Patients: is It Time to Revise Atazanavir Dosages?

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Apr 16

PMID 25875091

Citations 10

Authors

Cristina Gervasoni

Paola Meraviglia

Davide Minisci

Laurenzia Ferraris

Agostino Riva

Simona Landonio

Valeria Cozzi

Nitin Charbe

Lara Molinari

Giuliano Rizzardini

Emilio Clementi

Massimo Galli

Dario Cattaneo

Affiliations

Soon will be listed here.

Abstract

Introduction: Ritonavir-boosted atazanavir (ATV/r) is a relatively well tolerated antiretroviral drug. However, side effects including hyperbilirubinemia, dyslipidemia, nephrolithiasis and cholelithiasis have been reported in the medium and long term. Unboosted ATV may be selected for some patients because it has fewer gastrointestinal adverse effects, less hyperbilirubinemia and less impact on lipid profiles.

Methods: We investigated the distribution of ATV plasma trough concentrations according to drug dosage and the potential relationship between ATV plasma trough concentrations and drug-related adverse events in a consecutive series of 240 HIV-infected patients treated with ATV/r 300/100 mg (68%) or ATV 400 mg (32%).

Results: 43.9% of patients treated with ATV/r 300/100 mg had ATV concentrations exceeding the upper therapeutic threshold. A significant and direct association has been observed between the severity of hyperbilirubinemia and ATV plasma trough concentrations (ATV concentrations: 271 [77-555], 548 [206-902], 793 [440-1164], 768 [494-1527] and 1491 [1122-1798] ng/mL in patients with grade 0, 1, 2, 3 and 4 hyperbilirubinemia, respectively). In an exploratory analysis we found that patients with dyslipidemia or nephrolitiasis had ATV concentrations significantly higher (582 [266-1148], and 1098 [631-1238] ng/mL, respectively) (p<0.001), as compared with patients with no ATV-related complications (218 [77-541] ng/mL).

Conclusions: A significant proportion of patients treated with the conventional dosage of ATV (300/100) had plasma concentrations exceeding the upper therapeutic threshold. These patients that are at high risk to experience ATV-related complications may benefit from TDM-driven adjustments in ATV dosage with potential advantages in terms of costs and toxicity.

Citing Articles

Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV.

Lahiri C, Mehta C, Sykes C, Weiser S, Palella F, Lake J AIDS Res Hum Retroviruses. 2023; 39(12):644-651.

PMID: 37140468 PMC: 10712367. DOI: 10.1089/AID.2022.0185.

Ureterolithiasis in Human Immunodeficiency Virus (HIV) Patients Treated with Single-Use Ureteroscope: A Case Report.

Xiong L, Loo N, Lu Z, Xu X, Wei G Am J Case Rep. 2022; 23:e938608.

PMID: 36567520 PMC: 9801066. DOI: 10.12659/AJCR.938608.

Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected men.

Palella Jr F, Li X, Gupta S, Estrella M, Phair J, Margolick J AIDS. 2018; 32(10):1247-1256.

PMID: 29561293 PMC: 7406064. DOI: 10.1097/QAD.0000000000001807.

Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.

McMillan J, Cobb D, Lin Z, Banoub M, Dagur R, Branch Woods A J Pharmacol Exp Ther. 2018; 365(2):272-280.

PMID: 29476044 PMC: 5878674. DOI: 10.1124/jpet.117.247288.

Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Phung N, Kuncze K, Okochi H, Louie A, Benet L, Ofokotun I Rapid Commun Mass Spectrom. 2018; 32(5):431-441.

PMID: 29315954 PMC: 5848502. DOI: 10.1002/rcm.8058.

References

Ferraris L, Vigano O, Peri A, Tarkowski M, Milani G, Bonora S . Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. J Antimicrob Chemother. 2012; 67(9):2236-42. DOI: 10.1093/jac/dks175. View

Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K . High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012; 55(9):1262-9. DOI: 10.1093/cid/cis621. View

Jansen K, Sonnerborg A, Brockmeyer N, Thalme A, Svedhem V, Dupke S . Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses. 2012; 29(3):564-73. PMC: 3698683. DOI: 10.1089/aid.2012.0092. View

Laprise C, Baril J, Dufresne S, Trottier H . Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up. AIDS Patient Care STDS. 2013; 27(7):378-86. PMC: 3704117. DOI: 10.1089/apc.2013.0009. View

Hamada Y, Nishijima T, Komatsu H, Teruya K, Gatanaga H, Kikuchi Y . Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?. PLoS One. 2013; 8(7):e69845. PMC: 3713059. DOI: 10.1371/journal.pone.0069845. View

Nishijima T, Shimbo T, Komatsu H, Hamada Y, Gatanaga H, Kikuchi Y . Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection. J Antimicrob Chemother. 2014; 69(5):1385-9. DOI: 10.1093/jac/dkt514. View

De Nicolo A, Simiele M, Calcagno A, Abdi A, Bonora S, Di Perri G . Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. Antimicrob Agents Chemother. 2014; 58(7):4042-7. PMC: 4068548. DOI: 10.1128/AAC.00104-14. View

Lennox J, Landovitz R, Ribaudo H, Ofotokun I, Na L, Godfrey C . Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014; 161(7):461-71. PMC: 4412467. DOI: 10.7326/M14-1084. View

van Schaik R, van der Heiden I, van den Anker J, Lindemans J . CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002; 48(10):1668-71. View

10.

Carey D, Amin J, Boyd M, Petoumenos K, Emery S . Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010; 65(9):1878-88. DOI: 10.1093/jac/dkq231. View

11.

Schipani A, Siccardi M, DAvolio A, Baietto L, Simiele M, Bonora S . Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother. 2010; 54(12):5242-50. PMC: 2981241. DOI: 10.1128/AAC.00781-10. View

12.

Evans W, McLeod H . Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003; 348(6):538-49. DOI: 10.1056/NEJMra020526. View

13.

Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M . Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol. 2005; 28(2):119-25. View

14.

Rotger M, Taffe P, Bleiber G, Gunthard H, Furrer H, Vernazza P . Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005; 192(8):1381-6. DOI: 10.1086/466531. View

15.

Le Tiec C, Barrail A, Goujard C, Taburet A . Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005; 44(10):1035-50. DOI: 10.2165/00003088-200544100-00003. View

16.

Smith D, Jeganathan S, Ray J . Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials. 2006; 7(1):34-8. DOI: 10.1310/0KX0-H9VH-99EE-5D0L. View

17.

Pacanowski J, Poirier J, Petit I, Meynard J, Girard P . Atazanavir urinary stones in an HIV-infected patient. AIDS. 2006; 20(16):2131. DOI: 10.1097/01.aids.0000247571.88256.90. View

18.

Chang H, Pella P . Atazanavir urolithiasis. N Engl J Med. 2006; 355(20):2158-9. DOI: 10.1056/NEJMc061892. View

19.

Anderson P, Lichtenstein K, Gerig N, Kiser J, Bushman L . Atazanavir-containing renal calculi in an HIV-infected patient. AIDS. 2007; 21(8):1060-2. DOI: 10.1097/QAD.0b013e3280c56ae1. View

20.

Chan-Tack K, Truffa M, Struble K, Birnkrant D . Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS. 2007; 21(9):1215-8. DOI: 10.1097/QAD.0b013e32813aee35. View